Midday Market Review on April 9: SSE Index Drops 0.73% in Half-Day, Computing Power Hardware Stocks Strengthen Against the TrendWallstreetcn·Apr 8 at 10:30 PM000001+0.72%301201+2.44%
CHENGDA PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 16.7733 million yuan, a decrease of 58.47%Zhitong·Oct 27, 2025 at 06:32 AM301201+2.44%
CHENGDA PHARMA: Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its holdings by no more than 7.27%Zhitong·Sep 5, 2025 at 06:34 AM301201+2.44%
Shibeikang announced the completion of Series B financing, with listed company CHENGDA PHARMA as the exclusive strategic investorZhitong·Aug 26, 2025 at 09:01 PM301201+2.44%
CHENGDA PHARMA released its performance for the first half of the year, with a net profit attributable to the parent company of 12.8244 million yuan, a year-on-year decrease of 49.06%Zhitong·Aug 25, 2025 at 06:19 AM301201+2.44%
Innovative drug concept stocks are repeatedly active, HitGen and CHENGDA PHARMA both rise over 10%Zhitong·Jul 21, 2025 at 08:52 PM688222+4.98%301201+2.44%
CHENGDA PHARMA was reduced by 1.15% of its shares by shareholder Qianhai ShengtaiZhitong·Jun 25, 2025 at 03:51 AM301201+2.44%
CHENGDA PHARMA's shareholder Qianhai Shengtai plans to reduce its holdings by no more than 3.23%Zhitong·May 7, 2025 at 08:15 AM301201+2.44%
CHENGDA PHARMA released its first-quarter performance, turning from profit to a loss of 1.4 million yuanZhitong·Apr 24, 2025 at 06:18 AM301201+2.44%
CHENGDA PHARMA was reduced by 860,000 shares by its major shareholder Qianhai ShengtaiZhitong·Mar 12, 2025 at 04:50 AM301201+2.44%
CHENGDA PHARMA issues a profit warning, expecting a net loss of 21 million to 29 million yuan for the fiscal year 2024, turning from profit to loss year-on-yearZhitong·Jan 16, 2025 at 04:38 AM301201+2.44%
CHENGDA PHARMA: Expected net loss of RMB 21 million to RMB 29 million in 2024Zhitong·Jan 16, 2025 at 04:18 AM301201+2.44%
